Key facts
- Drug classes: Mounjaro's active drug, tirzepatide, is a dual GIP + GLP-1 receptor agonist; Ozempic's active drug, semaglutide, is a single GLP-1 receptor agonist. Both are peptide analogs of gut incretin hormones.
- Approved use: both are FDA-approved for type 2 diabetes only. The weight-loss versions are separate brands — tirzepatide as Zepbound, semaglutide as Wegovy.
- Head-to-head (SURPASS-2): tirzepatide beat semaglutide 1 mg on HbA1c (down to −2.30 vs −1.86 points) and on weight (−12.4 kg vs −6.2 kg at the top doses) over 40 weeks.
- Route & schedule: both are once-weekly subcutaneous injections given from a prefilled pen.
- Heart evidence: Ozempic carries an FDA cardiovascular risk-reduction indication backed by SUSTAIN-6; Mounjaro's SURPASS-CVOT was noninferior to dulaglutide, not proven superior.
- Approval status: both FDA-approved and prescription-only; both carry a rodent thyroid C-cell tumor boxed warning.
- Makers: Mounjaro by Eli Lilly; Ozempic by Novo Nordisk.
What is the difference between Mounjaro and Ozempic?
The names get used interchangeably, but they are two different drugs from two different companies. Ozempic is Novo Nordisk's brand of semaglutide. Mounjaro is Eli Lilly's brand of tirzepatide. Both are once-weekly injections you give yourself under the skin from a prefilled pen, and both were designed and approved to treat type 2 diabetes. That is where the overlap ends.
The core difference is how many hormone receptors each molecule switches on. Semaglutide is a modified copy of the human hormone GLP-1 and works through the single GLP-1 receptor. Tirzepatide is a purpose-built 39-amino-acid peptide that activates two incretin receptors at once — GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). That second receptor is the whole reason tirzepatide exists as a distinct drug, and it is the mechanistic story behind most of the head-to-head results below. Both sit inside the broader family of GLP-1 receptor agonists, so almost everything in this comparison traces back to that one difference in receptor targeting.
Same class, different molecules
GLP-1 is an incretin hormone released by intestinal L-cells after a meal. It boosts glucose-dependent insulin secretion, suppresses the counter-hormone glucagon, slows how fast the stomach empties, and signals fullness in the brainstem and hypothalamus — physiology mapped in detail long before any of these drugs existed (PubMed 17928588). Because the insulin effect is glucose-dependent, it eases off as blood sugar normalizes, which is why this class rarely causes low blood sugar on its own unless combined with insulin or a sulfonylurea. Ozempic works by stretching that natural signal: a fatty-acid chain binds albumin and pushes the half-life to about a week.
Mounjaro adds GIP agonism on top of GLP-1. GIP is the other major incretin, and for years it was written off as therapeutically useless because GIP responsiveness looks blunted in type 2 diabetes. Tirzepatide challenged that. Layering GIP activation onto GLP-1 appears to improve insulin sensitivity in fat tissue, influence how the body handles lipids, and — through GIP receptors in the brain — reinforce appetite suppression while possibly softening the nausea signal. Reviews of incretin pharmacology stress that receptor selectivity, signaling bias and dose intensity all contribute, and that head-to-head trials, not mechanism alone, decide which drug does more (PubMed 33767808). The wider role of these gut hormones in appetite and metabolism is reviewed in PubMed 34067710.
What is each one actually approved for?
This is the single most misunderstood point in the whole comparison, so it is worth stating plainly: neither Mounjaro nor Ozempic is FDA-approved for weight loss. Both are approved to improve blood sugar in adults with type 2 diabetes, alongside diet and exercise. The weight-loss drugs people are usually picturing are the same molecules under different brand names — tirzepatide sold as Zepbound for obesity and obstructive sleep apnea, and semaglutide sold as Wegovy for chronic weight management. The difference between Ozempic and Wegovy is not the drug; it is the label, the approved doses and the indication.
Ozempic's label goes a step further than glucose alone. It also carries an FDA indication to reduce the risk of major cardiovascular events in adults who have both type 2 diabetes and established cardiovascular disease, and semaglutide has since gained a kidney-disease indication as well. Mounjaro's approved use, by contrast, is type 2 diabetes. So when people ask which is "stronger," part of the honest answer is that the two brands are not approved for identical jobs. Prescribing either one purely to lose weight is off-label — legal and common, but a distinction that matters enormously for insurance coverage, as the cost section explains.
Mounjaro vs Ozempic head-to-head: SURPASS-2
The two drugs were tested directly against each other in SURPASS-2, and because both Mounjaro and Ozempic are diabetes brands, this trial is the most relevant head-to-head for the brand-versus-brand question. SURPASS-2 randomized 1,879 adults with type 2 diabetes already taking metformin to tirzepatide at 5, 10 or 15 mg or to semaglutide at 1 mg, all once weekly, and ran for 40 weeks (PubMed 34170647).
On the primary endpoint — the change in HbA1c, the standard marker of average blood sugar — tirzepatide won at every dose. It lowered HbA1c by about 2.01, 2.24 and 2.30 percentage points at 5, 10 and 15 mg, versus 1.86 points for semaglutide 1 mg. Weight loss followed the same shape: roughly 7.6, 9.3 and 11.2 kg across the three tirzepatide doses, versus about 5.7 kg for semaglutide. A large share of tirzepatide participants reached an HbA1c below 5.7%, which is technically the non-diabetic range. Statistically, tirzepatide met noninferiority and then superiority on the glycemic endpoint.
SURPASS-2 at a glance: 1,879 adults with type 2 diabetes on metformin, 40 weeks, tirzepatide 5/10/15 mg vs semaglutide 1 mg once weekly. HbA1c change roughly −2.0 to −2.3 points (tirzepatide) vs −1.9 points (semaglutide). Weight change up to about −12.4 kg at tirzepatide 15 mg vs about −6.2 kg for semaglutide 1 mg. Gastrointestinal side effects were common in both arms and broadly similar in character.
One caveat keeps this from being a clean knockout: SURPASS-2 compared tirzepatide against the 1 mg dose of semaglutide, which was the maximum Ozempic dose available when the trial was designed. A higher 2 mg dose was approved later. That stronger dose narrows the glycemic gap, though the published head-to-head evidence still favors tirzepatide. The broader review of GLP-1 head-to-head studies puts SURPASS-2 in context alongside the rest of the class (PubMed 33767808).
The numbers side by side
The table lines up the two brands across the dimensions people actually weigh. It summarizes published trial and label data, not a recommendation.
| Dimension | Mounjaro (tirzepatide) | Ozempic (semaglutide) |
|---|---|---|
| Drug class | Dual GIP + GLP-1 receptor agonist | GLP-1 receptor agonist |
| Maker | Eli Lilly | Novo Nordisk |
| FDA-approved use | Type 2 diabetes | Type 2 diabetes; cardiovascular risk reduction in T2D + CVD |
| Weight-loss twin brand | Zepbound | Wegovy |
| Route & schedule | Weekly subcutaneous injection (pen) | Weekly subcutaneous injection (pen) |
| Head-to-head A1c (SURPASS-2, 40 wk) | −2.01 to −2.30 points | −1.86 points (1 mg) |
| Head-to-head weight (SURPASS-2, 40 wk) | up to −12.4 kg | −6.2 kg (1 mg) |
| Cardiovascular outcomes trial | SURPASS-CVOT vs dulaglutide (noninferior) | SUSTAIN-6 vs placebo (event reduction) |
| Boxed warning | Thyroid C-cell tumors (rodent) | Thyroid C-cell tumors (rodent) |
| FDA status | Approved, prescription-only | Approved, prescription-only |
Which causes more weight loss?
Even though neither drug is approved for it, weight is why most people search this comparison, so it deserves a straight answer. In SURPASS-2, the head-to-head diabetes trial, tirzepatide produced roughly double the weight loss of semaglutide 1 mg — about 12.4 kg at 15 mg versus 6.2 kg. That pattern holds when you step outside the diabetes brands and look at the dedicated obesity programs. Tirzepatide's SURMOUNT-1 obesity trial reported mean weight loss near 20.9% on the 15 mg dose over 72 weeks (PubMed 35658024), while semaglutide's STEP 1 reported about 14.9% over 68 weeks (PubMed 33567185). Even in people who also had type 2 diabetes, tirzepatide's SURMOUNT-2 trial produced 12.8% to 14.7% loss (PubMed 37385275).
Real-world data has echoed the trials. Large observational studies of people taking the two drugs for weight have found tirzepatide users more likely to hit 5%, 10% and 15% loss milestones than semaglutide users over a year. So on the weight question specifically, the direction is consistent: Mounjaro's molecule tends to take off more weight than Ozempic's. That said, individual results vary widely, a meaningful fraction of the weight lost on either drug is lean mass, and both were studied alongside diet and activity counseling — not as a substitute for it. For the deeper dive into the molecules behind the brands, see our full tirzepatide vs semaglutide breakdown and the overview of peptides studied for weight loss.
Mounjaro vs Ozempic side effects
The two brands share a side-effect fingerprint because they share a mechanism rooted in the gut. Nausea, diarrhea, vomiting and constipation lead the list for both, are mostly mild to moderate, show up during dose escalation, and tend to settle once the dose is stable. In SURPASS-2 the head-to-head rates were close: nausea affected roughly 17% to 22% of tirzepatide users across doses versus about 18% on semaglutide 1 mg, with diarrhea and vomiting following a similar overlapping pattern and no statistically significant tolerability winner. A systematic review and meta-analysis of tirzepatide trials put its numbers in context — nausea in 20.4% of users versus 10.5% of controls, diarrhea 16.2% versus 8.6%, vomiting 9.1% versus 4.9% (PubMed 37908927).
Does one brand win on tolerability? On the direct evidence, no. Neither Mounjaro nor Ozempic was clearly gentler in SURPASS-2, and the deciding factor in practice is usually how an individual handles each step-up in dose rather than the molecule itself. Both also share the less common but clinically important signals — gallbladder disease, which any rapid weight loss can trigger; acute pancreatitis; injection-site reactions; and gastric emptying delayed enough to matter before anesthesia. Both labels carry the rodent thyroid C-cell tumor boxed warning and the same contraindication in people with a personal or family history of medullary thyroid carcinoma or MEN2. None of that is something to self-manage; it is exactly the sort of thing a prescriber screens for.
Heart and kidney evidence
This is the dimension where the diabetes brands diverge most, and it favors Ozempic. Weight and blood sugar are surrogates; what many clinicians ultimately care about is whether a drug prevents heart attacks, strokes and deaths — and here Ozempic's semaglutide has the more established, label-level record.
Semaglutide's SUSTAIN-6 trial enrolled 3,297 adults with type 2 diabetes at high cardiovascular risk and followed them for just over two years. Major adverse cardiovascular events — cardiovascular death, nonfatal heart attack or nonfatal stroke — were significantly lower on semaglutide than placebo (PubMed 27633186). That result underpins Ozempic's FDA cardiovascular risk-reduction indication, and semaglutide has since added a chronic-kidney-disease indication in type 2 diabetes on top of it.
Tirzepatide's cardiovascular evidence is newer and framed differently. SURPASS-CVOT randomized 13,299 adults with type 2 diabetes and atherosclerotic cardiovascular disease to tirzepatide or dulaglutide — an older GLP-1 agonist that already has proven cardiovascular benefit — and followed them for a median of about four years. The composite endpoint occurred in 12.2% on tirzepatide versus 13.1% on dulaglutide, meeting noninferiority but not superiority (PubMed 41406444). In plain terms: tirzepatide is at least as protective as an established GLP-1 drug in that population, but it has not shown a placebo-beating event reduction the way semaglutide has. For the diabetes-brand heart question, that gives Ozempic the stronger hand.
Cost, coverage and shortages
On price the two are more alike than different, and neither is cheap. US list prices for both have run around or above $1,000 a month before insurance. What complicates coverage is the approval quirk from earlier: because Mounjaro and Ozempic are approved for type 2 diabetes, many plans cover them for that diagnosis but not for off-label weight loss, and US Medicare Part D has historically been barred from covering drugs prescribed purely to lose weight. Manufacturer savings cards, direct self-pay vial channels and periodic price cuts have brought real costs down for some patients. Which brand is cheaper for a specific person usually comes down to their plan, their diagnosis on the prescription, and the offers active that month — not the molecule.
Both drugs also spawned a large gray market during their shortages, when US compounding pharmacies were temporarily allowed to make copies. As the FDA declared each shortage resolved — tirzepatide in late 2024, semaglutide in early 2025 — that permission wound down and routine mass compounding of both ended. What persists is unregulated vials sold online as "research chemicals" or "not for human consumption." These are not approved drugs, are subject to no pharmaceutical quality control, and independent testing of similar products has repeatedly found inconsistent content and purity. PepMate does not recommend or link to any source of peptides; for how the regulatory lines are drawn, see are peptides legal.
So which one is better?
For the job both are actually approved to do — controlling type 2 diabetes — the head-to-head evidence gives Mounjaro's tirzepatide the edge on the numbers: a bigger HbA1c drop and roughly double the weight loss versus Ozempic's semaglutide 1 mg in SURPASS-2. If maximum blood-sugar and weight effect is the goal, that is the direction the data points. But "better" is not a one-word answer, because Ozempic holds the stronger cardiovascular record through SUSTAIN-6 and carries FDA indications — heart-risk and kidney — that Mounjaro does not. Ozempic also has more years of real-world use and, in Rybelsus, an oral cousin of the same molecule.
So the honest verdict is that the winner depends on the goal and the person. Tolerability, insurance coverage, kidney function, other medications, cardiovascular history and whether the prescription is even for diabetes all shift the balance. None of those variables is something to self-adjudicate, and this article deliberately gives no dosing or protocol. The choice between these two brands — including whether either is appropriate at all — belongs with a licensed prescriber. For the molecule-level comparison behind the brands, see tirzepatide vs semaglutide; for what may eventually eclipse both, the triple agonist retatrutide is worth watching (PubMed 37366315). Background on how incretin drugs are engineered is summarized in PubMed 31050435.
Whichever brand a clinician chooses, both behave like treatments for a chronic condition rather than a short course. When semaglutide was withdrawn after a lead-in, participants regained about two-thirds of their lost weight within a year and their cardiometabolic gains reversed with it (PubMed 35441470). Tirzepatide shows the same pattern on stopping. That is a strong argument for tracking exactly what happens on either drug — dose day, titration steps, weight and side effects — week to week.
Frequently asked questions
What is the difference between Mounjaro and Ozempic?
Ozempic is a brand of semaglutide, which activates one incretin receptor, GLP-1. Mounjaro is a brand of tirzepatide, which activates two, GIP and GLP-1, so it is a dual agonist. Both are once-weekly injection pens approved for type 2 diabetes, made by different companies: Mounjaro by Eli Lilly, Ozempic by Novo Nordisk.
Is Mounjaro or Ozempic better for weight loss?
In the SURPASS-2 trial in type 2 diabetes, Mounjaro's tirzepatide produced about 12.4 kg of weight loss at its 15 mg dose over 40 weeks, versus about 6.2 kg for Ozempic's semaglutide at 1 mg. Real-world studies show a similar edge for tirzepatide. Neither drug is FDA-approved for weight loss itself; the approved weight-loss versions are Zepbound and Wegovy.
Is Mounjaro or Ozempic approved for weight loss?
Neither. Mounjaro and Ozempic are both FDA-approved to treat type 2 diabetes, not obesity. The same molecules are sold under different brands for weight management: tirzepatide as Zepbound and semaglutide as Wegovy. Prescribing Mounjaro or Ozempic purely for weight loss is off-label, and insurance coverage often depends on which brand and indication is on the prescription.
Which has fewer side effects, Mounjaro or Ozempic?
Both share a gastrointestinal side-effect profile: nausea, diarrhea, vomiting and constipation, mostly mild to moderate and clustered around dose increases. In SURPASS-2 the rates were broadly similar, with nausea around 17 to 22 percent for tirzepatide versus about 18 percent for semaglutide 1 mg. Neither drug showed a clear tolerability advantage. Individual tolerance of dose escalation usually matters more than the molecule.
Which lowers blood sugar more, Mounjaro or Ozempic?
In the head-to-head SURPASS-2 trial, tirzepatide lowered HbA1c more than semaglutide 1 mg at every dose, by about 2.01, 2.24 and 2.30 percentage points at 5, 10 and 15 mg versus 1.86 for semaglutide. That trial used the 1 mg Ozempic dose available at the time; a stronger 2 mg dose was approved later, which narrows but does not erase the gap.
Which is better for the heart, Mounjaro or Ozempic?
Ozempic has the more established cardiovascular record. In the SUSTAIN-6 trial, semaglutide cut major cardiovascular events versus placebo in adults with type 2 diabetes, which supports Ozempic's heart-risk-reduction indication. Mounjaro's SURPASS-CVOT trial showed tirzepatide was noninferior to dulaglutide, an established GLP-1 drug, but not proven superior. So Ozempic has label-level heart evidence that Mounjaro does not yet match.
Can you switch from Ozempic to Mounjaro?
Switching between GLP-1 drugs happens often in practice, usually when blood sugar or weight stalls, side effects are hard to tolerate, or insurance changes. The head-to-head trials did not test switching, so there is no published protocol for it, and dose selection and timing are decisions for a prescriber. PepMate does not recommend switching or provide dosing; discuss any change with your clinician.
Is Mounjaro or Ozempic cheaper?
Both carry US list prices around or above 1,000 dollars a month before insurance, and coverage is inconsistent. Because both are approved for type 2 diabetes, many plans cover them for that diagnosis while excluding off-label weight-loss use. Manufacturer savings cards and self-pay channels change the real cost. Which is cheaper for a given person usually comes down to their plan and current offers, not the molecule.
Sources
Every claim above traces to peer-reviewed literature indexed on PubMed:
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2) — PubMed 34170647
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) — PubMed 27633186
- Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (SURPASS-CVOT) — PubMed 41406444
- Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis — PubMed 37908927
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — PubMed 35658024
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) — PubMed 37385275
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — PubMed 33567185
- Weight regain and cardiometabolic effects after withdrawal of semaglutide — PubMed 35441470
- GLP-1 receptor agonists: an updated review of head-to-head clinical studies — PubMed 33767808
- The physiology of glucagon-like peptide 1 — PubMed 17928588
- The Role of Peptide Hormones Discovered in the 21st Century in the Regulation of Appetite and Metabolism — PubMed 34067710
- Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency — PubMed 31050435
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity — PubMed 37366315